SCHEMBL2192122

SCHEMBL2192122

CSCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO)C(=O)N[C@H]([C]=O)CCC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.38
BMP1 P13497 1/20 0.35
NMT2 O60551 2/20 0.35
NMT1 P30419 2/20 0.35
BACE1 P56817 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
TLR2 O60603 2/20 0.34
TSHR P16473 1/20 0.33
PTH1R Q03431 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676216 0.91 GRIN2D (0.43) NMT2NMT1BACE1GRIN2DGRIN3B
SCHEMBL14743758 0.91 BACE1 (0.41) FOLH1NMT2NMT1BACE1
SCHEMBL3122465 0.87 GRIN2D (0.42) NMT2NMT1BACE1GRIN2DGRIN3B
SCHEMBL2183164 0.86 DPP4 (0.40) BMP1BACE1TSHRFNTAFNTB
SCHEMBL2470628 0.86 BACE1 (0.41) FOLH1NMT2NMT1BACE1GRIN2D
SCHEMBL2196205 0.84 NMT1 (0.43) NMT2NMT1BACE1GRIN2DGRIN3B
SCHEMBL2202327 0.83 FOLH1 (0.43) FOLH1BMP1BACE1GRIN2DGRIN3B
SCHEMBL31157722 0.83 FOLH1 (0.52) FOLH1BACE1TLR2FNTAFNTB
SCHEMBL2183342 0.83 FOLH1 (0.44) FOLH1BMP1BACE1GRIN2DGRIN3B
SCHEMBL2196575 0.82 FOLH1 (0.41) FOLH1BMP1BACE1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP FOLH1 64/4885BMP1 3740/4885NMT2 283/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP FOLH1 64/4885BMP1 3740/4885NMT2 283/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS FOLH1 31/4885BMP1 1697/4885NMT2 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.